(INNO:CSE)
InnoCan Pharma Is A Pharmaceutical Company That Specializes In The Development Of New Drug Platforms Which Combine Unique Properties of Cannabinoids
WHY INNOCAN?
InnoCan has 3 fully operating divisions to address the market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.
PHARMACEUTICAL – THE GUIDED MISSILE
- Revolutionary Technology Targeting Lungs Infected With Coronavirus or other viral infections
- Done By Combining CBD with Stem Cell Particles (Exosomes)
- Research & Licensing Agreement with Tel Aviv University
- Developing CLX, The ICBM Ballistic Missile Of Coronavirus Lung Infections
- Separate breakthrough delivery and control release technology that enables the injection of CBD.
CONSUMER RETAIL – DERMA COSMETICS
Completed Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) CBD Premium Facial Serum on Skin Hydration
- A Premium Derma Cosmetics Brand
- Containing Highly Concentrated Ingredients Formulated with CBD
- Manufacturing & Supply Agreements – Europe and United States
- Manufacturing Has Commenced For 9 Products As Of Q2 2020
- Distribution Agreements – United Kingdom and Ireland
OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF
- Patent-Pending CBD Pain Relief Brand
- Versions Include Spray, Roll-On and Cream
- Relief & Go Spray – First Product Being Manufactured
- FDA Technical Validation
- FDA Approval To Commence Marketing In The United States
- Manufacturing Commencement
- New Jersey (United States Market)
- Portugal (Asia and Europe Markets)
- Sales Commenced In H2 2020 during September
SEEING IS BELIEVING
FULL DISCLOSURE: Innocan Pharma is an advertising client of AGORA Internet Relations Corp.
Tags: CBD Derma Cosmetics, CBD stocks, CSE, Innocan, Relief & Go Pain Relief Spray, small cap, smallcap stocks, stocks, tsx, tsx-v